Condition
JAK2 Mutation
Total Trials
4
Recruiting
1
Active
1
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
2Total
P 1 (1)
P 2 (1)
Trial Status
Not Yet Recruiting1
Unknown1
Completed1
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT07249840Phase 1Not Yet RecruitingPrimary
Ropeginterferon for High Risk JAK2 Clonal Hematopoiesis
NCT04243122Phase 2Completed
Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients
NCT05123326Recruiting
Global Coagulation Assessment in Portal Vein Thrombosis and Budd-Chiari Syndrome
NCT04527666Unknown
Anticoagulation in Gastroesophageal Varices and JAK2 Mutation
Showing all 4 trials